TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26006702
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral immediate-release onapristone after an overnight fast
Study: 26006702
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral immediate-release onapristone within 30 min of a high-fat, high-calorie meal
Study: 26006702
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral immediate-release onapristone
Study: 20367670
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser therapy after 60-90 min ALA application
Study: 16308351
Drug: Intravenous isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isoproterenol (isoprenaline): 6, 12 and 24 ng (kg fat‐free mass)‐1 min‐1
Study: 16308351
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (vitamin C; 0.04 g (kg fat‐free mass)‐1)
Study: 9088775
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro (LP)
Study: 9088775
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Insulin (H)
Study: 9088775
Drug: Porcine Insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine Insulin (P)
Study: 8462534
Drug: Intravenous diclofenac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac, 100 mg
Study: 29905973
Drug: Teriparatide 20 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg/d plus sham vibration 10 min/d (n=20)
Study: 29905973
Drug: Teriparatide 20 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg/d plus vibration 10 min/d (n=21)
Study: 29905973
Drug: Teriparatide 20 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg/d after 12-month extension
Study: 27196589
Drug: Split-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose regimen
Study: 25207759
Drug: Temperature-modulated photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature-modulated photodynamic therapy (PDT) with 20% ALA and 10 J/cm, 417-nm blue light, heated during incubation
Study: 22776824
Drug: Dapagliflozin 1
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 1 mg
Study: 20055989
Drug: Lower tidal
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower tidal volume (6 ml/kg)
Study: 20055989
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume (10 ml/kg)
Study: 8810613
Drug: AutoSet nCPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: AutoSet nCPAP titration
Study: 4020121
Drug: timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol (10 mg/day, n = 14)
Study: 4020121
Drug: methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyldopa (250 mg/day, n = 16)
Study: 4020121
Drug: hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (25 mg/day) and amiloride (2.5 mg/day)
Study: 26729245
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (hydroxychloroquine, methotrexate, mycophenolate mofetil, prednisolone) in addition to standard topical therapy
Study: 26729245
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy plus a short course of prednisolone given orally
Study: 17914310
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid (4 mg/mL) and heparin (10 IU/mL) lock
Study: 17914310
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fusidic acid-heparin lock)
Study: 16182311
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg i.v. eight hourly
Study: 16182311
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g six hourly
Study: 29632995
Drug: Trimodulin (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodulin (42 mg IgM/kg/day)
Study: 24122814
Drug: CSL112 (3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (3.4 g or 6.8 g, administered intravenously once or twice weekly)
Study: 24122814
Drug: CSL112 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (multiple infusions)
Study: 24122814
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered intravenously)
Study: 21219987
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg of haemagglutinin (HA) of each of three influenza strains on days 0 and 14
Study: 21219987
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of haemagglutinin (HA) on day 0 and saline placebo on day 14
Study: 21219987
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine dose groups
Study: 6437286
Drug: Diazepam (0.29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.29 mg/kg, iv) + Physostigmine
Study: 6437286
Drug: Morphine (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.21 mg/kg, iv) + Physostigmine
Study: 6437286
Drug: Physostigmine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine alone (3 mg, iv)
Study: 27323608
Drug: Jiangzhi Xiaoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangzhi Xiaoban Tablet (JXT), 0.45 g/tablet, 4 tablets each time, 3 times per day for 8 weeks
Study: 27323608
Drug: Simvastatin Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin Tablet, 20 mg/tablet, 1 tablet each time, once per evening for 8 weeks
Study: 24497220
Drug: Brotizolam 0.25
Normalized name: brotizolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.25 mg/day
Study: 17413465
Drug: Active mobilization
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active mobilization program (Mechanical Diagnosis and Therapy)
Study: 14723508
Drug: Bronchodilator drug
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator drug (Terbutaline)
Study: 11028835
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonists (specifically 2 mg intravenous tropisetron)
Study: 1622045
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) 0.3 microgram/kg infusion over 15 min after cardiopulmonary bypass
Study: 1622045
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion over 15 min after cardiopulmonary bypass
Study: 6090539
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir therapy
Study: 23710796
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (10 therapy sessions over 3 months, followed by 4 maintenance sessions over 6 months)
Study: 22025630
Drug: Bedtime dosing
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dosing of at least one BP-lowering medication
Study: 15339577
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu Capsule (FZHY Capsule)
Study: 15339577
Drug: Heluo Shugan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heluo Shugan Capsule (Control)
Study: 10898841
Drug: Implant-supported overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported overdentures on a transmandibular implant system (n = 21)
Study: 10898841
Drug: Implant-mucosa-supported overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-mucosa-supported overdentures on 2 IMZ implants (n = 20)
Study: 9151586
Drug: Bioceram sapphire
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioceram sapphire implants with overdentures
Study: 1358044
Drug: Nebivolol 1
Normalized name: nebivolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 1 mg/day for 48 hours
Study: 1358044
Drug: Nebivolol 2.5
Normalized name: nebivolol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 2.5 mg/day for 72 hours
Study: 1358044
Drug: Nebivolol 2.5
Normalized name: nebivolol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 2.5 mg for one week then 5 mg for 5 weeks
Study: 9818307
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (RT)
Study: 29920323
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g high molecular weight oat β-glucan
Study: 23852152
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg) associated with double-dose clopidogrel (150 mg)
Study: 23852152
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel alone
Study: 21048432
Drug: Mixed model
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed model for cholesterol-reducing treatments
Study: 21048432
Drug: General linear
Approvals — FDA: no, EMA: no, PMDA: no
Description: General linear model for cholesterol-reducing treatments
Study: 21048432
Drug: Mixed model
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed model for sleeplessness treatments
Study: 21048432
Drug: General linear
Approvals — FDA: no, EMA: no, PMDA: no
Description: General linear model for sleeplessness treatments
Study: 20179692
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (manometric‐assisted pelvic relaxation and simulated defecation training)
Study: 10193351
Drug: Intrapleural streptokinase,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural streptokinase, 250,000 IU daily for three days
Study: 3393781
Drug: Ciprofloxacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (oral administration)
Study: 3393781
Drug: Cefotaxime (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (intravenous administration)
Study: 26444334
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection (i.v.) of PHC
Study: 26444334
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection (i.m.) of PHC
Study: 21820860
Drug: 1.0mg fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0mg fluoride tablet (Group A)
Study: 21820860
Drug: 0.5mg fluoride
Normalized name: Quflora Pediatric with 0.5mg Fluoride Quatrefolic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg fluoride tablet (Group B)
Study: 16620590
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose (5 microg) after negative conversion of anti-HBs
Study: 16620590
Drug: Intradermal revaccinees
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal revaccinees
Study: 16620590
Drug: Intramuscular revaccinees
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular revaccinees
Study: 9212136
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg epidural morphine preemptively 60 min before surgery
Study: 9212136
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg epidural morphine at the conclusion of surgery
Study: 3296607
Drug: Aminophylline (5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5.6 mg x kg‐1)
Study: 3296607
Drug: Thiopental (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (7 mg x kg‐1)
Study: 28134053
Drug: r-tPA treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-tPA treatment
Study: 26013140
Drug: Anaesthetics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetics and lavage (50 mL saline)
Study: 21718959
Drug: Ulinastatin 150,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin 150,000 U twice daily for 3 days
Study: 19065051
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of inspired oxygen (FiO(2)) alone
Study: 14656717
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (1.26 micromol.kg(‐1).min(‐1) x 6 h, n = 9)
Study: 14656717
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose of insulin (1 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 6)
Study: 14656717
Drug: Pharmacological dose
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological dose of insulin (20 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 9)
Study: 9661645
Drug: GHRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH plus GHRP-6 (90 micrograms each, administered intravenously as a bolus)
Study: 56591
Drug: Transfusion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion to a Hb of 10‐12 g/dl (group A)
Study: 56591
Drug: Moderate hypertransfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypertransfusion to a Hb of 14‐16 g/dl (group B)
Study: 31758247
Drug: GI‐pill gastrointestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI‐pill gastrointestinal electronic capsule
Study: 31758247
Drug: X‐ray granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: X‐ray granule capsule
Study: 22939518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lisinopril and irbesartan (n = 70)
Study: 22939518
Drug: Lisinopril (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (n = 35)
Study: 22939518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lisinopril and irbesartan
Study: 19969216
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5% drops
Study: 17197857
Drug: Bupivacaine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (3.3 mg ED95) combined with 1.5 microg sufentanil
Study: 17197857
Drug: Ropivacaine (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (4.8 mg ED95) combined with 1.5 microg sufentanil
Study: 17197857
Drug: Levobupivacaine (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (5.0 mg ED95) combined with 1.5 microg sufentanil
Study: 12173010
Drug: CPT MBF
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT MBF corrected by RPP in smokers (0.65 ± 0.12 ml g(‐1) min(‐1))
Study: 12173010
Drug: Rest MBF
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest MBF in smokers (0.86 ± 0.11 ml g(‐1) min(‐1))
Study: 12173010
Drug: Hyperaemic MBF
Normalized name: 1-36 human humoral hypercalcemic factor
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperaemic MBF during ATP infusion in smokers (3.20 ± 1.12 ml g(‐1) min(‐1))
Study: 8553632
Drug: Zontac (histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zontac (histamine H2-receptor blocking agent) administered intravenously 50 mg thrice a day for 3 days, then orally 150 mg twice a day for 3 weeks
Study: 30925074
Drug: Intensive dysarthria
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dysarthria therapy (three 40-minute sessions per week for six weeks)
Study: 26013051
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity interval training (HIIT) at 85‐95% of HRmax, performed twice a week for 10 weeks on spinning bikes.
Study: 25411597
Drug: Ipragliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin (all doses)
Study: 21752511
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 0.125 mg/mL epinephrine
Study: 21752511
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 0.006 mg/mL epinephrine
Study: 21752511
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 0.012 mg/mL epinephrine
Study: 16764623
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (n = 52)
Study: 15385832
Drug: Everolimus starting
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus starting dose of 0.75 mg bid (n = 112)
Study: 15385832
Drug: Everolimus starting
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus starting dose of 1.5 mg bid (n = 125)
Study: 15385832
Drug: Cyclosporine dosing
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine dosing
Study: 15385832
Drug: Everolimus C0
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus C0 between 3 and 8 ng/mL
Study: 7658304
Drug: 0.25% itraconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% itraconazole cream
Study: 7658304
Drug: 0.50% itraconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50% itraconazole cream
Study: 18090696
Drug: Propofol (120.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (120.9 +/- 50.0 mg)
Study: 18090696
Drug: Methohexital (83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (83 +/- 26.3 mg)
Study: 16275379
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized hazelnut extract
Study: 15833834
Drug: Letrozole therapy
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole therapy for 1 month
Study: 15833834
Drug: Letrozole therapy
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole therapy for 3 months
Study: 9884249
Drug: C2 (700-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2 (700-1000 ng/ml)
Study: 9884249
Drug: C0 (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: C0 (100-200 ng/ml)
Study: 9884249
Drug: C2 (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2 (300-600 ng/ml)
Study: 8571773
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal blanket suture using nonabsorbable material (silk)
Study: 1535202
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia (2.5 mg/kg)
Study: 1535202
Drug: Thiamylal-enflurane anesthesia
Normalized name: thiamylal
DrugBank: Thiamylal (DB01154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamylal-enflurane anesthesia (4 mg/kg)
Study: 6498579
Drug: Propranolol 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.01 mg X kg‐1 IV, administered two minutes prior to induction
Study: 6498579
Drug: Propranolol 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.01 mg X kg‐1 IV, administered five minutes prior to induction
Study: 6498579
Drug: Propranolol 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.01 mg X kg‐1 IV, administered eight minutes prior to induction
Study: 6498579
Drug: Saline pretreatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline pretreatment, administered five minutes prior to induction
Study: 25936814
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (total dose of 6.0 Gy applied in 6 fractions of 1.0 Gy three times a week)
Study: 25936814
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injections (1 ml injection of 40 mg methylprednisolone and 0.5 ml 1% lidocaine under the guidance of palpation)
Study: 23566060
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (30 g/day) for 30 days
Study: 16491348
Drug: Gastrografin (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (350 ml) of three different concentrations
Study: 14684757
Drug: Supplemental vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental vitamin C (approximately 70 mg/day)
Study: 9233735
Drug: rhIL‐1ra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐1ra (100 mg) followed by a 72‐hr continuous intravenous infusion of rhIL‐1ra (2.0 mg/kg/hr)
Study: 9233735
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) followed by a 72‐hr continuous intravenous infusion of placebo
Study: 8497364
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to metronidazole gel
Study: 3305215
Drug: 18-month maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18-month maintenance therapy
Study: 3305215
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (IDMTX) plus intrathecal methotrexate
Study: 29476019
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg fresolimumab
Study: 29476019
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg fresolimumab
Study: 29476019
Drug: Focal radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal radiotherapy (three doses of 7.5 Gy)
Study: 26622051
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone (250 mg) every 2 weeks for 24 weeks
Study: 26622051
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL saline) every 2 weeks for 24 weeks